Trial | NCT00518219  Report issue

Title

To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
To Compare the Efficacy and Safety of TW vs Valsartan in the MN

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    68
The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.
Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.

Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.
Study Started
Jul 31
2007
Primary Completion
Mar 31
2009
Study Completion
Sep 30
2009
Last Update
May 27
2010
Estimate

Drug TW

TW,120mg/d

  • Other names: TW,Tripterygium wilfordii Hook.f

immunosuppressor Experimental

TW 120mg/d，Valsartan,160mg/d

Criteria 

Inclusion Criteria:

Biopsy-proven idiopathic membranous nephropathy
Nephrotic syndrome with proteinuria (> 4 g/day) and serum albumin < 30 g/dl
Age over 18 with informed consent

Exclusion Criteria:

Patient with abnormal liver function tests
Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days,
Active/serious infection,
Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
No Results Posted